Boric acid exert anti-cancer effect in poorly differentiated hepatocellular carcinoma cells via inhibition of AKT signaling pathway

Basit Öğe Kaydı
dc.authoridKahraman, Erkan/0000-0003-0051-416X
dc.authorscopusid57204097891
dc.authorscopusid26662691100
dc.authorwosidKahraman, Erkan/AAE-6696-2019
dc.contributor.authorKahraman, Erkan
dc.contributor.authorGoker, Erdem
dc.date.accessioned2023-01-12T19:55:32Z
dc.date.available2023-01-12T19:55:32Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractBackground: The possible anti-cancer properties of boron, a trace element for humans, have been demonstrated in various experimental and epidemiological studies, although the effects of boron on liver cancer are unclear. In the present study we evaluate the effects of boric acid on the cell lines of hepatocellular carcinoma (HCC) of the liver, as the leading form of liver cancer, for which a poorly-differentiated HCC cell line (Mahlavu cell line) was used. Methods: The anti-cancer effect of boric acid was investigated with a cell viability assay, apoptosis analysis, cell migration analysis, cell morphology analysis, colony formation assay and 3D cell culture techniques. Also, the effect of boric acid on the AKT signaling pathway was determined through a western blot analysis. Results: Boric acid was found to reduce cell viability in a dose- and time-dependent manner, and decreased survival, colony formation ability, migration capability and HCC cell tumor spheroid growth in HCC cell lines, while also inducing apoptosis, autophagy and morphological alteration. Furthermore, boric acid inhibited AKT phosphorylation, and anticancer biological responses in HCC cells were observed only in cells in which AKT phosphorylation was suppressed by boric acid. Conclusion: Our results suggest that boric acid might be a promising therapeutic candidate in hepatocellular carcinoma via the inhibition of AKT signaling pathway.en_US
dc.description.sponsorshipAcademic Oncology Association from Turkeyen_US
dc.description.sponsorshipThis study was funded by Academic Oncology Association from Turkey.en_US
dc.identifier.doi10.1016/j.jtemb.2022.127043
dc.identifier.issn0946-672X
dc.identifier.issn1878-3252
dc.identifier.pmid35868168en_US
dc.identifier.scopus2-s2.0-85134802428en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.jtemb.2022.127043
dc.identifier.urihttps://hdl.handle.net/11454/76701
dc.identifier.volume73en_US
dc.identifier.wosWOS:000839412700007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Gmbhen_US
dc.relation.ispartofJournal of Trace Elements in Medicine and Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBoric aciden_US
dc.subjectBoronen_US
dc.subjectLiver canceren_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectCancer drugsen_US
dc.subjectDietary Boronen_US
dc.subjectHuman Prostateen_US
dc.subjectIn-Vitroen_US
dc.subjectCanceren_US
dc.subjectMigrationen_US
dc.subjectGrowthen_US
dc.subjectPhosphorylationen_US
dc.subjectPrognosisen_US
dc.subjectPi3k/Akten_US
dc.subjectRodentsen_US
dc.titleBoric acid exert anti-cancer effect in poorly differentiated hepatocellular carcinoma cells via inhibition of AKT signaling pathwayen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu